Pfizer and BioNTech granted U.S. EUA for booster dose for kids 5-11 years

Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series

BDR Pharma receives Rs. 685 crore of PE investment

Multiples is the first private equity (PE) investor in the company

Moderna announces advancements in mRNA platform science for application across multiple diseases

Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery

Adroit BioMed launches Fortisil range of skincare products

PCI Pharma Services announces US $100 million investment in New England

Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends

The focus in FY 23 for most players would be international markets and ROW exports: Ankit Poddar, director, Candle Partners

Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.

Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY

The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt

Zydus receives tentative approval from USFDA for Selexipag tablets

The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad

Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore

The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings

Pfizer sets up global drug development centre in Chennai

The facility is among 12 centres established worldwide, and the first in Asia